Owkin has partnered with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer. Takeaway Points Owkin has ...

Bank of America Securities analyst Sachin Jain has reiterated their bullish stance on AZN stock, giving a Buy rating on September 30. Sachin ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has accepted the supplemental biologics license application ...

Wednesday announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan in combination with volrustomig for the treatment of clear cell renal cell carcinoma or ccRCC ...

The Israeli-American unicorn company ImmunAI has signed a multi-year cooperation agreement with the pharmaceutical giant ...

We recently published a list of 10 Best Major Stocks to Invest In According to Analysts. In this article, we are going to ...

The solution will use Owkin's data network and artificial intelligence to prescreen for gBRCA mutations in breast cancer directly from digital pathology slides.

(Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and ...

We recently compiled a list of 8 Cheap Growth Stocks to Buy According to Analysts. In this article, we will look at where ...

AstraZeneca’s share price has fallen following unfavourable results for one of its new drugs, but others look good, and ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...